Menbutone (CAS: 3562-99-0, C15H14O4), China's first specialized choleretic drug for animals, was developed for over eight years. Unlike traditional choleretics, it operates via a unique non-cholic acid-dependent pathway, addressing key gaps in animal digestive health. This innovation ended foreign monopolies in veterinary digestive therapeutics and established China's independent R&D capabilities in the field.

Menbutone’s Pharmacological Mechanism

1. Bile Secretion Enhancement: Directly activates Na+/K+-ATPase in hepatocytes, increasing bile output 2-5-fold.

3. Selective Targeting: Its 4-methoxynaphthoylpropionic acid structure specifically modulates hepatobiliary function.

Menbutone demonstrates significant therapeutic efficacy in piglet diarrhea treatment, achieving a 25.7% reduction in recovery time (from 5.2 to 3.8 days on average) with a 92.3% cure rate, while maintaining a 5-fold higher tolerance threshold than standard doses. Its broad-spectrum applications include effective management of cattle ketosis (40% faster blood ketone clearance) and sheep rumen atony in ruminants, as well as canine liver dysfunction in companion animals, while remaining safe for pregnant animals without causing uterine muscle impairment. Pharmacokinetic studies reveal rapid absorption with peak plasma concentration achieved within 1 hour, sustained therapeutic effects lasting approximately 10 hours, and predominant hepatobiliary excretion.

The Advantage of Sinoway’s Menbutone:

Purity: ≥99.5% (HPLC).